Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19743706 | 0.85 | HPGD (0.40) | CNR2HPGDTSHRRAD51MEN1 | |
| SCHEMBL29849086 | 0.83 | RAD51 (0.41) | CNR2HPGDTSHRRAD51MEN1 | |
| SCHEMBL19743703 | 0.83 | RAD51 (0.41) | CNR2HPGDTSHRRAD51MEN1 | |
| SCHEMBL19744182 | 0.79 | CNR2 (0.53) | CNR2HPGDTSHRRAD51KMT2A | |
| SCHEMBL19744039 | 0.72 | HPGD (0.40) | CNR2HPGDTSHRRAD51KMT2A | |
| SCHEMBL14911407 | 0.71 | KMT2A (0.51) | CNR2HPGDRAD51KMT2A | |
| SCHEMBL19743700 | 0.70 | CNR2 (0.57) | CNR2RAD51KMT2A | |
| SCHEMBL19743336 | 0.70 | CNR2 (0.62) | CNR2 | |
| SCHEMBL18494378 | 0.68 | CNR2 (0.44) | CNR2HPGDTSHRP2RX7 | |
| SCHEMBL19743343 | 0.67 | HPGD (0.37) | CNR2HPGDTSHRRAD51KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415366-B | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3475283-B1 | NOVEL[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-08-11 | — | — | EP | disclosed |
| CN-109311895-B | Novel [1,2,3] triazolo [4,5-d ] pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3475280-B1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457686-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190127386-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3475283-A1 | NOVEL[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| EP-3475280-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017220544-A1 | NOVEL[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017220516-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | CNR2 167/4885HPGD 1645/4885TSHR 838/4885 |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | TYMS, DPYD, TYMP | CNR2 209/4885HPGD 1044/4885TSHR 656/4885 |
| US-20190127386-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | CNR2 167/4885HPGD 1645/4885TSHR 838/4885 |
| US-10457686-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | TYMS, DPYD, TYMP | CNR2 209/4885HPGD 1044/4885TSHR 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.